Gene Solutions Showcases Breakthroughs in Oncology at SSO ASM 2025

At the Singapore Society of Oncology Annual Scientific Meeting 2025, held on October 15, 2025, Gene Solutions presented significant advancements in cancer care, emphasizing a shift from reactive to proactive approaches. The symposium titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors” attracted leading oncologists and molecular biology experts from across the Asia-Pacific region. The focus was on how Molecular Residual Disease (MRD) and artificial intelligence-powered multi-omics technologies are transforming precision oncology, reinforcing Singapore’s position as a key player in global health innovation.

The discussions centered on the role of MRD assays, which utilize circulating tumor DNA (ctDNA) to monitor cancer at a molecular level. Presenters highlighted several potential benefits of this innovative approach, including enhanced monitoring capabilities and improved patient outcomes. Gene Solutions’ platform stands out for integrating DNA, RNA, and AI-enhanced multi-omics signals, leading to a comprehensive analysis of tumor profiles. This multifaceted approach not only boosts ctDNA sensitivity but also aids in identifying complex gene fusions and predicting the locations of primary tumors, allowing for more personalized treatment strategies.

Recent studies published in JCO Oncology Advances and Nature’s npj Breast Cancer underscore the efficacy of ctDNA-based MRD testing in anticipating early recurrences of cancer and fostering cost-effective monitoring strategies in real-world scenarios. Gene Solutions operates a CAP-accredited laboratory in Singapore, which plays a pivotal role in its mission to advance genomic research and promote precision oncology throughout the region.

Collaborative Efforts for Enhanced Patient Care

Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, emphasized the importance of collaboration in advancing these innovative technologies. She stated, “Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively.” Lindstroem extended an invitation to oncologists, researchers, and healthcare partners in the Asia-Pacific to join forces in enhancing data-driven, personalized care aimed at improving patient outcomes across various healthcare systems.

By fostering scientific collaboration and innovation, Gene Solutions aims to play a significant role in the future of cancer care, spearheading initiatives that align with the latest advancements in genomic testing.

About Gene Solutions

Gene Solutions is a multinational biotechnology company specializing in genetic testing and research within the Asia-Pacific region. The company harnesses the power of Next-Generation Sequencing (NGS) and artificial intelligence to provide a diverse portfolio of advanced solutions. With over two million genetic tests conducted, Gene Solutions is recognized for its proprietary research, CAP-accredited laboratories, and its contributions to the field of precision medicine through clinical studies and regional collaborations.

For further insights from the symposium, visit: [Gene Solutions News](https://genesolutions.com/news/gene-solutions-showcases-mrd-and-multi-omics-advances-at-sso-asm-2025-in-singapore).